EULAR Recommendations: Diagnosis and Management of Rheumatic Adverse Events due to Cancer Immunotherapy

EULAR points to consider for the diagnosis and management of rheumatic immune-related adverse events due to cancer immunotherapy with checkpoint inhibitors – Annals of Rheumatic Diseases

Related: Clinical characteristics of rheumatic syndromes associated with checkpoint inhibitors therapy – Rheumatology AND Musculoskeletal and Rheumatic Diseases Induced by Immune Checkpoint Inhibitors: A Review of the Literature – Current Drug Safety AND Immune-related Adverse Events Associated with Cancer Immunotherapy: A Review for the Practicing Rheumatologist – The Journal of Rheumatology AND NCCN Guidelines Insights: Management of Immunotherapy-Related Toxicities (guidelines and reviews on the subject)